Carisma Therapeutics, Inc. (OTCPK: CARM)
Health Care · Biotechnology · US
$0.00
-37.50% today · -98.7% 1Y
Carisma Therapeutics, Inc. (OTCPK: CARM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $20.92K and employs 46 people.
Over the last twelve months the share price has lost 98.7%, trading between 0.00 and 0.10.
Tweenvest scores Carisma Therapeutics, Inc. across four factors: quality 30/100, value 59/100. Its strongest factor is value.
CARM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $20.92K
- Revenue (TTM)
- $52.63M
- P/E
- 0.00
- EPS
- 0.19
- Dividend yield
- —
- Beta (5Y)
- -28.28
- 52-week high
- $0.10
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 41.85M
- Employees
- 46
- Next earnings
- —
About Carisma Therapeutics, Inc.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
- ISIN
- US14216R1014
- Founded
- 2016
- Listed since
- Feb 6, 2014
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Nascent Biotech, Inc.OTCPK: NBIO | $34.57K | $0.00 | +100.00% |
| Myrexis, Inc.OTCPK: MYRX | $27.58K | $0.00 | — |
| Burzynski Research Institute, Inc.OTCPK: BZYR | $26.29K | $0.00 | -89.74% |
| Biostax Corp.OTCPK: BTAX | $21.65K | $— | — |
| Dragon Life Science Holdings Group, Inc.OTCPK: NOHO | $20.04K | $0.00 | — |
| T2 Biosystems, Inc.OTCPK: TTOO | $19.63K | $0.00 | +16.67% |
| Neovacs S.A.ENXTPA: ALNEV | $17.12K | €0.10 | -3.90% |
| Scopus BioPharma Inc.OTCPK: SCPS | $16.83K | $0.00 | -33.33% |
Figures last refreshed Oct 18, 2026.